EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Ruxolitinib improves hematopoietic regeneration by restoring mesenchymal stromal cell function in acute graft-versus-host disease

Yan Lin, Quan Gu, Shihong Lu, Zengkai Pan, Zining Yang, Yapu Li, Shangda Yang, Yanling Lv, Zhaofeng Zheng, Guohuan Sun, Fanglin Gou, Chang Xu und 11 weitere

Journal of Clinical Investigation · 01.08.2023 · 133 (15)

DOI: 10.1172/jci162201 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 01.08.2023. Verfasst von Yan Lin und 22 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Experimental Hematology, Department of Hematology, The First People's Hospital of Changzhou, Third Affiliated Hospital of Soo…. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Graft vs Host Disease, Mesenchymal Stem Cells. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Ministry of Science and Technology of China, Haihe Laboratory of Cell Ecosystem Innovation Fund, the CAMS Initiative for Innovative Medicine.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Acute graft-versus-host disease (aGVHD) is a severe complication of allogeneic hematopoietic stem cell transplantation. Hematopoietic dysfunction accompanied by severe aGVHD, which may be caused by niche impairment, is a long-standing clinical problem. However, how the bone marrow (BM) niche is damaged in aGVHD hosts is poorly defined. To comprehensively address this question, we used a haplo-MHC-matched transplantation aGVHD murine model and performed single-cell RNA-Seq of nonhematopoietic BM cells. Transcriptional analysis showed that BM mesenchymal stromal cells (BMSCs) were severely affected, with a reduction in cell ratio, abnormal metabolism, compromised differentiation potential, and defective hematopoiesis-supportive function, all of which were validated by functional assays. We found that ruxolitinib, a selective JAK1/2 inhibitor, ameliorated aGVHD-related hematopoietic dysfunction through a direct effect on recipient BMSCs, resulting in improved proliferation ability, adipogenesis/osteogenesis potential, mitochondria metabolism capacity, and crosstalk with donor-derived hematopoietic stem/progenitor cells. By inhibiting the JAK2/STAT1 pathway, ruxolitinib maintained long-term improvement of aGVHD BMSC function. Additionally, ruxolitinib pretreatment in vitro primed BMSCs to better support donor-derived hematopoiesis in vivo. These observations in the murine model were validated in patient samples. Overall, our findings suggest that ruxolitinib can directly restore BMSC function via the JAK2/STAT1 pathway and, in turn, improve the hematopoietic dysfunction caused by aGVHD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematopoietic Stem Cell TransplantationGraft vs Host DiseaseMesenchymal Stem CellsHumansAnimalsMiceDisease Models, AnimalAcute DiseaseNitrilesPyrazolesPyrimidines

Stichwörter der Autor:innen

Bone marrow transplantationStem cells

Substanzen

ruxolitinibNitrilesPyrazolesPyrimidines

Autor:innen und Institutionen

  • State Key Laboratory of Experimental Hematology, Department of Hematology, The First People's Hospital of Changzhou, Third Affiliated Hospital of Soochow University, Changzhou, China.
  • State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical…
  • Center for Stem Cell Medicine, Chinese Academy of Medical Sciences, Department of Stem Cell and Regenerative Medicine, Peking Union Medical College, Tianjin, China.
  • State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, National Research Center for Translational Medicine, Shanghai Rui Jin Hospital, and.
  • Collaborative Innovation Center of Hematology, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Department of Cell Biology, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, China.

Förderung

  • the Ministry of Science and Technology of China
  • Haihe Laboratory of Cell Ecosystem Innovation Fund
  • the CAMS Initiative for Innovative Medicine
  • the CAMS Fundamental Research Funds for Central Research Institutes
  • Distinguished Young Scholars of Tianjin
  • the National Natural Science Foundation of China

Zitieren

APA

Lin, Y., Gu, Q., Lu, S., Pan, Z., Yang, Z., Li, Y., Yang, S., Lv, Y., Zheng, Z., Sun, G., Gou, F., Xu, C., Zhao, X., Wang, F., Wang, C., Yuan, S., Xie, X., Cao, Y., Liu, Y., …, & Hu, X. (2023). Ruxolitinib improves hematopoietic regeneration by restoring mesenchymal stromal cell function in acute graft-versus-host disease. Journal of Clinical Investigation, 133(15). https://doi.org/10.1172/jci162201

Vancouver

Lin Y, Gu Q, Lu S, Pan Z, Yang Z, Li Y, et al. Ruxolitinib improves hematopoietic regeneration by restoring mesenchymal stromal cell function in acute graft-versus-host disease. Journal of Clinical Investigation. 2023;133(15). doi:10.1172/jci162201

BibTeX
@article{Lin2023,
  author = {Lin, Yan and Gu, Quan and Lu, Shihong and Pan, Zengkai and Yang, Zining and Li, Yapu and Yang, Shangda and Lv, Yanling and Zheng, Zhaofeng and Sun, Guohuan and Gou, Fanglin and Xu, Chang and Zhao, Xiangnan and Wang, Fengjiao and Wang, Chenchen and Yuan, Shiru and Xie, Xiaobao and Cao, Yang and Liu, Yue and Gu, Weiying and Cheng, Tao and Cheng, Hui and Hu, Xiaoxia},
  title = {Ruxolitinib improves hematopoietic regeneration by restoring mesenchymal stromal cell function in acute graft-versus-host disease},
  journal = {Journal of Clinical Investigation},
  year = {2023},
  volume = {133},
  number = {15},
  doi = {10.1172/jci162201}
}
Kostenlos starten →